Skip to main content
17 January 2021
Last updated:
Saturday 16 January 2021

User account menu

  • Log in
  • Register & Subscribe

Search this site:

 

Primary links

  • Home
  • News
  • About MedNous
  • Research Directory
  • Contact Us

Positive data for Kymriah in follicular lymphoma

Tuesday 4 August 2020
Country

Switzerland

The chimeric antigen receptor (CAR) T cell therapy Kymriah (tisagenlecleucel) has delivered positive data in a Phase 2 study of patients with relapsed or refractory follicular lymphoma, the second most common form of non-Hodgkin lymphoma, Novartis announced on 4 August. 

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Clinical Research
Regenerative Medicine
Company News

Select a News Category

  • Clinical Research
  • Company News
  • Finance, Grants, Deals
  • IPR & Legal
  • Regenerative Medicine
  • Regulation & Policy
  • Research & University News

Recent Appointments

Klaas Zuideveld becomes CEO of Versameb
Saturday January 16 2021
MorphoSys appoints new CFO
Thursday January 7 2021
Sam Herbert becomes COO at Clinigen
Wednesday January 6 2021
Wolfgang Baiker becomes CEO at Adrenomed
Wednesday January 6 2021
Alligator Bioscience appoints new CMO
Tuesday December 29 2020

© 2021 Evernow Publishing Ltd. Powered by Drupal.